Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control

Radiotherapy and Oncology

Volumn 82, Issue 2, 2007, Pages 160-166

  De Meerleer, Gert O ^a   Fonteyne, Valérie H ^a   Vakaet, Luc ^a   Villeirs, Geert M ^a   Denoyette, Ludwig ^a   Verbaeys, Antony ^b   Lummen, Nicolas ^b   De Neve, Wilfried J ^a  

^a Department of Radiation Therapy ^*

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biochemical control; IMRT; Morbidity; Prostate cancer

Indexed keywords

ANTIANDROGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; DISEASE DURATION; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATURIA; HIGH RISK POPULATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RELAPSE FREE SURVIVAL; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; UROGENITAL TRACT DISEASE;

AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL ANALYSIS; SURVIVORS; TREATMENT OUTCOME;

EID: 33847183937     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.12.007     Document Type: Article

References (44)

1. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
2. Beckendorf V., Guerif S., Le Prise E., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1056-1065
3. Bolla M., Gonzalea D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer and goserelin. N Engl J Med 337 (1997) 295-300
4. Cox J.D., Stelz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
5. D'Amico A.V., Whittington R., Kaplan I., et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pre-treatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys 37 (1997) 1053-1058
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy of external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95 (2002) 281-286
7. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiation therapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
8. De Gersem W., Claus F., De Wagter C., and De Neve W. An anatomy-based beam segmentation tool for intensity-modulated radiation therapy and its application to head-and-neck cancer. Int J Radiat Oncol Biol Phys 51 (2001) 849-859
9. De Meerleer G., Vakaet L., Meersschout S., et al. Intensity-modulated radiation therapy as primary therapy for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60 (2004) 777-787
10. De Meerleer G., Villeirs G., Vakaet L., Delrue L.J., and De Neve W.J. The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiation therapy for prostate cancer. Strahlenther Onkol 180 (2004) 573-581
11. De Meerleer G., Vakaet L., De Gersem W.R., et al. Radiation therapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 47 (2000) 639-648
12. De Meerleer G., Vakaet L., De Gersem W., Villeirs G., and De Neve W. Direct segment aperture and weight optimization for intensity-modulated radiation therapy of prostate cancer. Strahlenther Onkol 180 (2004) 136-143
13. Diaz A., Roach M., Marquez C., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiation therapy for localised prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994) 323-329
14. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 397-405
15. Fiorino C., Cozzarini C., Vavssori V., et al. Relationships between DVH's and late rectal bleeding after radiation therapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
16. Gottschalk A.R., and Roach M. The use of hormonal therapy with radiation therapy for prostate cancer: analysis of prospective randomised trials. Br J Cancer 90 (2004) 950-954
17. Hanks G.E., Lee W.R., Hanlon A.L., Schultheiss T.E., and Hunt M.A. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pre-treatment prostate-specific antigen >10 ng/ml. Int J Radiat Oncol Biol Phys 35 (1996) 862-868
18. Hanks G.E., Hanlon A.L., Epstein B., and Horwitz E.M. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54 (2002) 427-435
19. Khoo V., Dearnaley D., Finnigan D., et al. Magnetic resonance imaging (MRI): considerations and applications in radiation therapy treatment planning. Radiother Oncol 42 (1997) 1-15
20. Kupelian P., Kuban D., Thames H., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2005) 415-419
21. Kupelian P.A., Katcher J., Levin H.S., and Klein E.A. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37 (1997) 1043-1052
22. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiation therapy <72 Gy, external beam radiation therapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiation therapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 8 (2004) 25-33
23. Lipincott JB. American Joint Committee on cancer. Manual for staging of cancer. Prostate, 5th ed. Philadelphia, PA; 1998.
24. Liu M., Pickles T., Agranovich A., et al. Impact of neo-adjuvant androgen ablation and other factors on late toxicity after external beam prostate radiation therapy. Int J Radiat Oncol Biol Phys 58 (2004) 59-67
25. Lukka H., Hayter C., Julian J.A., et al. Randomised trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
26. McCloskey S.A., Ellerbroek N.A., McCarthy A.W., et al. Treatment outcomes of three-dimensional conformal radiation therapy for localized prostate carcinoma. Cancer 101 (2004) 2693-2700
27. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiation therapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
28. Peeters S.T., Heemsbergen W.D., van Putten W.L.J., et al. Acute and late complications after radiation therapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
29. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiation therapy in prostate carcinoma - long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
30. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiation therapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
31. Pollack A., Zagars G.K., Starkschall G., et al. Conventional vs. conformal radiation therapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34 (1996) 555-564
32. Sanguineti G., Agostinelli F., Foppiano F., et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiation therapy for prostate carcinoma. Br J Cancer 86 (2002) 1843-1847
33. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 3-11
34. Storey M.R., Pollack A., Zagars G., et al. Complications from radiation therapy dose escalation in prostate cancer: preliminary results of a randomised trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
35. Teh B.S., Mai W.-Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys 49 (2001) 705-712
36. Vandecasteele K., De Neve W., Villeirs G., et al. Accuracy of ultrasound-guided prostate cancer (UGPP). Radiother Oncol 73 (2004) S410
37. Villeirs G.M., Verstraete K., De Neve W.J., and De Meerleer G.O. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol 76 (2005) 99-106
38. Villeirs G., Van Vaerenbergh K., Vakaet L., et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiation therapy for prostate cancer. Strahlenther Onkol 181 (2005) 424-430
39. Villeirs G.M., De Meerleer G.O., Verstraete K.L., and De Neve W.J. Magnetic resonance assessment of prostate localization variability in intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 1611-1621
40. Zagars G.K., Pollack A., and von Eschenbach A.C. Management of unfavourable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80 (1997) 764-775
41. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int Radiat Oncol Biol Phys 41 (1998) 491-500
42. Zelefsky M.J., Fuks Z., Wolfe T., et al. Locally advanced prostate cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy- a dose escalation study. Radiology 209 (1998) 169-174
43. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
44. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294 (2005) 1233-1239